Drugs / pabolizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05259540 | Jan 2023 → Dec 2025 | cervical cancer | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04427475 | Jun 2020 → Dec 2021 | non-small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07034326 Comparator | Jan 2025 → Dec 2028 expected | non-small cell lung carcinoma | Kong Fanming | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pabolizumab | “Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.” NCT07034326 ↗ |
| Action | Inhibit | “PD-1 inhibitors (pabolizumab)” NCT05259540 ↗ |